(429) adherence to PDE-5 inhibitors in patients with erectile dysfunction (ED) following spinal cord injury (SCI). real life data after 10 years of treatment
Abstract
PDE5Is are an effective treatment for ED in SCI individuals. A real-life cohort study was performed to evaluate the adherence to PDE5Is as well as the dropout rate, almost 10 years after the initiation of treatment.
97 SCI patients suffering from ED that were treated with PDE5Is were evaluated in 2015. Concomitant cardiovascular diseases, hormonal and psychiatric disorders were excluded. Efficacy was evaluated with IIEF5 and SEP2&3 questions. We re-evaluate our data now in order to assess the adherence to PDE5Is, almost 10 years after.
10 years after we collected data from 81 patients out of the original 87 responders.
From the sildenafil group, 18 out of 31 responders are still on, 6 on daily us tadalafil, 1 on intra-cavernosal injections (ICI), 1 died, 2 were lost in follow up, 2 are off treatment due to lack of sexual partner and 1 stopped the medication due to other comorbidities.
From the vardenafil group 5/13 still are on, 2 on sildenafil, 2 daily tadalafil, 1 on ICI, 1 without partner and 2 stopped due to comorbidities..
From the avanafil group, 3/7 are still on, 1 on sildenafil and 2 on daily tadalafil.
From the on demand tadalafil group, 7/22 are still on, 5 on daily tadalafil, 2 on sildenafil, 2 were lost in follow up, 1 died, 1 on ICI, 2 without partner and 2 stopped due to other comorbidities.
From daily tadalafil group, 9 are still on, 1 died, 1 on ICI, 2 on sildenafil, 1 underwent penile prosthesis implantation and 1 stopped the medication due to other…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 97 participants or records.
Read the paper
Related studies
- Antioxidant efficacy and the upregulation of Nrf2-mediated HO-1 expression by (+)-lariciresinol, a lignan isolated from Rubia philippinensis, through the activation of p38
- Anti-influenza virus activity of green tea by-products in vitro and efficacy against influenza virus infection in chickens
- Therapeutic Potential of Mesenchymal Stem Cells (MSCs) and MSC-Derived Extracellular Vesicles for the Treatment of Spinal Cord Injury
- The intratumoral administration of ferucarbotran conjugated with doxorubicin improved therapeutic effect by magnetic hyperthermia combined with pharmacotherapy in a hepatocellular carcinoma model
- Enhanced anticancer efficacy of TRAIL-conjugated and odanacatib-loaded PLGA nanoparticles in TRAIL resistant cancer
- In vivo tracking of bioorthogonally labeled T-cells for predicting therapeutic efficacy of adoptive T-cell therapy
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.